In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
From larvae to laundry: Sasol introduces insect oil-based surfactant
In Houston, Sasol has introduced a surfactant made from oil obtained from black soldier fly larvae.
Trade named LIVINEX IO 7, the insect-based surfactant meets...
Fungi fix: Dutch designer Dierkx shows mycelium can convert waste plastic into protein bars
In the Netherlands, designer Odette Dierkx has envisioned a new concept for producing protein bars: dried mycelium that has been fed waste plastics.
Dubbed...
Green toilet clean: Henkel taps LyondellBasell for biobased toilet cleaner packaging
In Germany, cleaning products giant Henkel is using biobased plastic from Houston’s LyondellBasell in its toilet cleaner packaging.
The packaging will specifically use LyondellBasell’s...